Potential of FX06 to prevent disease progression in hospitalized non-intubated COVID-19 patients — the randomized, EU-wide, placebo-controlled, phase II study design of IXION.
Saved in:
| Title: | Potential of FX06 to prevent disease progression in hospitalized non-intubated COVID-19 patients — the randomized, EU-wide, placebo-controlled, phase II study design of IXION. |
|---|---|
| Authors: | Kloka, Jan1 (AUTHOR), Friedrichson, Benjamin1 (AUTHOR), Dauth, Stephanie2,3 (AUTHOR), Foldenauer, Ann Christina2 (AUTHOR), Bulczak-Schadendorf, Anita2 (AUTHOR), Vehreschild, Maria J. G. T.4 (AUTHOR), Matos, Francisco Maio5 (AUTHOR), Riera-Mestre, Antoni6,7,8 (AUTHOR), van Asselt, Antoinette D. I.9 (AUTHOR), De Robertis, Edoardo10 (AUTHOR), Juskeviciene, Vilma Traskaite11 (AUTHOR), Meybohm, Patrick12 (AUTHOR), Tomescu, Dana13 (AUTHOR), Lacombe, Karine14 (AUTHOR), Stehouwer, Coen D. A.15,16 (AUTHOR), Zacharowski, Kai1 (AUTHOR) Kai.Zacharowski@kgu.de, on behalf of the IXION Collaboration Group (AUTHOR), Old, Oliver (AUTHOR), Ketomaeki, Markus (AUTHOR), Grebe, Lea (AUTHOR) |
| Source: | Trials. 8/19/2022, Vol. 23 Issue 1, p1-12. 12p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
